CA1326834C - Porphyrin derivatives - Google Patents

Porphyrin derivatives

Info

Publication number
CA1326834C
CA1326834C CA000490424A CA490424A CA1326834C CA 1326834 C CA1326834 C CA 1326834C CA 000490424 A CA000490424 A CA 000490424A CA 490424 A CA490424 A CA 490424A CA 1326834 C CA1326834 C CA 1326834C
Authority
CA
Canada
Prior art keywords
antibody
therapeutic agent
linker
gly
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000490424A
Other languages
English (en)
French (fr)
Inventor
John Walter Goers
Hurley Dalton King
Chyi Lee
Daniel James Coughlin
Richard Charles Siegel
John Dennies Rodwell
Thomas Joseph Mckearn
Vernon Leon Alvarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogen Corp
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/650,375 external-priority patent/US4867973A/en
Application filed by Cytogen Corp filed Critical Cytogen Corp
Application granted granted Critical
Publication of CA1326834C publication Critical patent/CA1326834C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA000490424A 1984-09-13 1985-09-11 Porphyrin derivatives Expired - Lifetime CA1326834C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65075484A 1984-09-13 1984-09-13
US650,375 1984-09-13
US06/650,375 US4867973A (en) 1984-08-31 1984-09-13 Antibody-therapeutic agent conjugates
US650,754 1984-09-13

Publications (1)

Publication Number Publication Date
CA1326834C true CA1326834C (en) 1994-02-08

Family

ID=27095841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000490424A Expired - Lifetime CA1326834C (en) 1984-09-13 1985-09-11 Porphyrin derivatives

Country Status (7)

Country Link
EP (1) EP0175617B1 (enExample)
AU (2) AU583854B2 (enExample)
CA (1) CA1326834C (enExample)
DE (1) DE3584559D1 (enExample)
DK (1) DK218386A (enExample)
GR (1) GR852217B (enExample)
WO (1) WO1986001720A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
GB8628398D0 (en) * 1986-11-27 1986-12-31 Central Blood Lab Authority Pharmaceutically-active conjugates
US4835258A (en) * 1986-12-24 1989-05-30 Northwestsern University Conjugation of aromatic amines or nitro-containing compounds with proteins or polypeptides by photoirradiation of the azide derivatives with ultraviolet light in order to produce antibodies against the haptens
WO1988005433A1 (en) * 1987-01-15 1988-07-28 Celltech Limited Thiol-reactive cross-linking reagents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
FR2610198B1 (fr) * 1987-02-03 1990-06-15 Ire Celltarg Sa Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
FR2611141B1 (fr) * 1987-02-20 1991-02-01 Int Rech Cancer Centre Ensemble ou kit pour utilisation comme agent pour la destruction selective de cellules transformees ou tumorales
EP0282057A3 (en) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
EP0336383A3 (en) * 1988-04-07 1990-08-16 Takeda Chemical Industries, Ltd. Novel recombinant human lymphotoxin
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
USRE39094E1 (en) 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
DE3827940A1 (de) * 1988-08-13 1990-03-01 Schering Ag 13,17-propionsaeure- und propionsaeurederivat- substituierte porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
GR890100827A (el) * 1988-12-21 1991-03-15 Abbott Lab Μέ?οδος παραγωγής παραγώγων τετραπεπτιδίων ως ανταγωνιστών CCK.
US5270302A (en) * 1988-12-21 1993-12-14 Abbott Laboratories Derivatives of tetrapeptides as CCK agonists
CA2056431A1 (en) * 1989-06-07 1990-12-08 David Dolphin Photosensitizing diels-alder porphyrin derivatives
US5308608A (en) * 1989-06-07 1994-05-03 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
WO1991000108A1 (en) * 1989-06-30 1991-01-10 Brunswick Corporation Antibody-oxidase conjugates with non-systemic substrates
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
CA2078118C (en) * 1990-04-25 1999-11-16 Paul A. Aristoff Cc-1065 analogs
CA2093361C (en) * 1990-10-05 2002-04-23 Michel Ringuet Porphyrin derivative
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
WO1997033620A2 (de) * 1996-03-15 1997-09-18 Pulsion Verw. Gmbh & Co. Medical Systems Kg Verbindungen zur behandlung von tumoren
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US6493570B1 (en) * 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US7648695B2 (en) 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
JP5689573B2 (ja) 1999-08-13 2015-03-25 プロヴェクタス ファーマテック，インク． 疾患の光線力学的療法のための改良された局所用薬品および方法
US20020049247A1 (en) 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
WO2005014049A2 (en) * 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
WO2005047507A1 (en) * 2003-11-12 2005-05-26 The Austin Research Institute Dna-carrier conjugate
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
EP2380909A1 (en) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019136335A1 (en) * 2018-01-05 2019-07-11 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970521A (en) * 1974-08-07 1976-07-20 Exxon Research And Engineering Company Immobilized glycoenzymes
CA1083508A (fr) * 1975-11-13 1980-08-12 Jacques Grange Supports porteurs de chaines laterales, procedes d'obtention de ces supports, procedes de fixation de composes organiques comportant un residu glucidique sur lesdits supports, produits et reactifs resultant de ladite fixation chimique
JPS52141882A (en) * 1976-05-20 1977-11-26 Hidetoshi Tsuchida Highhpolymeric complex of covalent type
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates

Also Published As

Publication number Publication date
AU4807185A (en) 1986-04-08
AU3016189A (en) 1989-07-13
GR852217B (enExample) 1986-01-14
DK218386D0 (da) 1986-05-12
DE3584559D1 (de) 1991-12-05
AU583854B2 (en) 1989-05-11
WO1986001720A1 (en) 1986-03-27
EP0175617A2 (en) 1986-03-26
DK218386A (da) 1986-07-11
EP0175617A3 (en) 1988-06-15
EP0175617B1 (en) 1991-10-30

Similar Documents

Publication Publication Date Title
CA1326834C (en) Porphyrin derivatives
US5156840A (en) Amine-containing porphyrin derivatives
US4867973A (en) Antibody-therapeutic agent conjugates
EP0088695B1 (en) Antibody conjugates
US4671958A (en) Antibody conjugates for the delivery of compounds to target sites
US4937183A (en) Method for the preparation of antibody-fragment conjugates
AU627785B2 (en) Vasopermeability-enhancing conjugates
US5112954A (en) Method of enhancing the effect of cytotoxic agents
AU588832B2 (en) Antibody-metal ion complexes
KR910000029B1 (ko) 효소와 항체의 공유 결합에 의해 결합된 접합체의 제조방법
AU621347B2 (en) Functionally specific antibodies
US4880935A (en) Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
EP0294392A1 (en) DIAGNOSTIC AND THERAPEUTIC CONJUGATES ASSOCIATED WITH ANTIBODY.
AU663582B2 (en) In vivo binding pair pretargeting
US5354554A (en) Crosslinked antibodies and processes for their preparation
JPH03504644A (ja) 架橋抗体とその製法
US6007817A (en) Vasopermeability enhancing immunoconjugates
Philpott et al. Selective binding and cytotoxicity of rat basophilic leukemia cells (RBL-1) with immunoglobulin E-biotin and avidin-glucose oxidase conjugates.
US5714149A (en) Crosslinked antibodies and processes for their preparation
US5151266A (en) Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies
EP0485749A2 (en) Chemical modification of antibodies for creating of immunoconjugates
JPS62500175A (ja) 抗体−治療剤接合体
FR2610198A1 (fr) Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
CA2000479C (en) Vasopermeability-enhancing conjugates

Legal Events

Date Code Title Description
MKEX Expiry
MKEX Expiry

Effective date: 20110208